A complementary strategy with maternal RSVpreF vaccination and nirsevimab immunization for otherwise unprotected and preterm infants in Germany would provide a greater benefit compared to nirsevimab alone, protecting substantially more infants at lower total costs.
Lade et al. (Wed,) studied this question.